Search
Cronos Group Inc
CRONAdd to Watchlist
3.220USD
-0.070-2.13%
Market hours 08/20, 15:19（ET）
1.19BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-19The current earnings forecast score of Cronos Group Inc is 7.00, ranking 115 out of 158 in the Pharmaceuticals industry. The average price target is 2.90, with a high of 2.90 and a low of 2.90.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.450
Target Price
+9.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Cronos Group Inc
CRON
2
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Regeneron Pharmaceuticals Inc
REGN
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cronos Group Inc's expected revenue for the next quarter?
Cronos Group Inc's expected revenue is 49.47M.
What is Cronos Group Inc's price target?
Analysts forecast that Cronos Group Inc's price target is USD 2.90, with the highest forecast at USD 2.90 and the lowest forecast at USD 2.90.
How have Cronos Group IncCRON's recent earnings per share performed?
The market expectation was USD 0.09, while Cronos Group IncCRON's earnings per share (EPS) for the previous quarter was USD 0.04. EPS for the next quarter is expected at USD 0.03.
What is the analyst rating for Cronos Group Inc?
Based on the ratings of Cronos Group Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.